268 related articles for article (PubMed ID: 28417621)
1. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
3. Up regulation of MMP9 gene expression in female patients with multiple sclerosis.
Hamedani SY; Taheri M; Sajjadi E; Omrani MD; Mazdeh M; Arsang-Jang S; Panah AS; Sayad A
Hum Antibodies; 2016; 24(3-4):59-64. PubMed ID: 28128762
[TBL] [Abstract][Full Text] [Related]
4. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis.
Rezaie Z; Taheri M; Kohan L; Sayad A
Hum Antibodies; 2016; 24(3-4):71-76. PubMed ID: 27792005
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
7. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.
Serana F; Imberti L; Amato MP; Comi G; Gasperini C; Ghezzi A; Martinelli V; Provinciali L; Rottoli MR; Sotgiu S; Stecchi S; Vecchio M; Zaffaroni M; Cordioli C; Capra R
PLoS One; 2014; 9(4):e94794. PubMed ID: 24733382
[TBL] [Abstract][Full Text] [Related]
8. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.
Cakal B; Uygunoglu U; Saip S; Altintas A; Siva A; Badur S
J Immunoassay Immunochem; 2014; 35(4):398-411. PubMed ID: 24547871
[TBL] [Abstract][Full Text] [Related]
9. Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients.
Matas E; Bau L; Martínez-Iniesta M; Romero-Pinel L; Mañé-Martínez MA; Martínez-Yélamos S
J Neurol; 2016 Apr; 263(4):722-9. PubMed ID: 26872667
[TBL] [Abstract][Full Text] [Related]
10. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
11. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.
Vallittu AM; Erälinna JP; Ilonen J; Salmi AA; Waris M
Acta Neurol Scand; 2008 Jul; 118(1):12-7. PubMed ID: 18081914
[TBL] [Abstract][Full Text] [Related]
12. Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.
Sayad A; Ghafouri-Fard S; Omrani MD; Noroozi R; Taheri M
Neurol Sci; 2017 Jun; 38(6):1093-1099. PubMed ID: 28386647
[TBL] [Abstract][Full Text] [Related]
13. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
[TBL] [Abstract][Full Text] [Related]
15. Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.
Libertinova J; Meluzinova E; Tomek A; Horakova D; Kovarova I; Matoska V; Kumstyrova S; Zajac M; Hyncicova E; Liskova P; Houzvickova E; Martinkovic L; Bojar M; Havrdova E; Marusic P
PLoS One; 2017; 12(1):e0169957. PubMed ID: 28081207
[TBL] [Abstract][Full Text] [Related]
16. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
17. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
18. IFNAR1 expression level in Iranian multiple sclerosis patients treated with IFN-B.
Sayad A; Kelarijani MK; Sajjadi E; Taheri M
Hum Antibodies; 2017; 26(1):17-22. PubMed ID: 28282804
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
20. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
Pachner A; Narayan K; Price N; Hurd M; Dail D
Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
